submitsd this has been determined with the amendments and arguments presented above.

In view of the above submissions, Applicant respectfully submits that the amended claims in the Application are clearly allowable over the prior art, and full reconsideration is requested.

Attached hereto as Exhibit A is a marked-up version of the changes made to the claims by the present amendment. The attached pages are entitled **"EXHIBIT A – CLAIMS WITH MARKINGS TO SHOW CHANGES".**

Also attached hereto as Exhibit B are the sheets that contain a clean set of all pending claims following entry of this amendment. These sheets are entitled **"EXHIBIT B – CLEAN SET OF ALL PENDING CLAIMS FOLLOWING ENTRY OF THE PRESENT AMENDMENT"**. All of the currently pending claims are consolidated in this list for the convenience of the Examiner.

Should the Examiner have any questions he/she is respectfully requested to contact Neil H. Hughes at (905) 771-6414 at his/her convenience.

Respectfully submitted,



Neil H. Hughes, P.Eng.
Registration No. 33,636
Agent for the Applicant

NHH:mse
Enclosures

EXHIBIT A

CLAIMS WITH MARKINGS TO SHOW CHANGES

Please amend the following claims.

1. (Amended) A process of making a solid pharmaceutical composition comprising moexipril magnesium, said process comprising the step of reacting moexipril or an acid addition salt thereof with an alkaline magnesium compound in the presence of a solvent so as to convert [most or all of] at least 70% of the moexipril or moexipril acid addition salt to moexipril magnesium.

5. (Twice Amended) The process of Claim 1 comprising the steps of:

i) adding the moexipril or acid addition salt thereof and the alkaline magnesium compound to solvent;

ii) using the resultant solution or suspension to wet granulate with[other] excipients to obtain a wet mass;

iii) drying the wet mass to obtain a dried mass; and

iv) further processing the dried mass into the solid pharmaceutical composition.

7. (Twice Amended) The process of Claim 1 comprising the steps of:

i) adding the moexipril or acid addition salt thereof to solvent;

ii) using the resultant solution or suspension to wet granulate a mixture of the alkaline magnesium compound and one or more [other] excipients to obtain wet mass;

iii) drying the wet mass to obtain a dried mass, and

iv) further processing the dried mass into the solid pharmaceutical composition.

8. (Twice Amended) The process of Claim 1 comprising the steps of:

i) mixing the moexipril or acid addition salt thereof and alkaline magnesium compound with one or more [other] excipients;

ii) adding a solvent and mixing to obtain a wet mass;

iii) drying the wet mass to obtain a dry mass; and

iv) further processing the dried mass into the solid pharmaceutical composition.

12. (Twice Amended) The process of any one of Claims 1, 2, 3, 5, 6, 7, or 8 wherein the percentage of the moexipril or acid addition salt converted to moexipril magnesium is [substantially] greater than [about] 80%.

13. (Twice Amended) The process of Claim 12 wherein the percentage of the moexipril or acid addition salt thereof converted to moexipril magnesium is [substantially] greater than 90%.

18. (Amended) The process of Claim 4 wherein the percentage of the moexipril or acid addition salt converted to moexipril magnesium is [substantially] greater than [about] 80%.